Gwo Xi Stem Cell Company has established the R&D center for cell therapy development since 2011. We are developing stem cell therapies that have the potential to transform the lives of people with degeneration diseases and rare diseases. Our production platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have three clinical trials are going in Taiwan, and one clinical trial is going in Vietnam by now. In future, we will have established the PIC/S GMP grade stem cell preparation factory (15,225 m2 built-out space) in Hsinchu Biomedical Science Park in Taiwan to put stem cell-based medicinal products into practice. Progressively, we are committed to continuing to develop stem cell therapy-related technologies that have broad potential of commercial applications to help the people with medical needs.

Manufacturing Platform

Introduction

The manufacturing platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have four clinical trials are going by now including GXHPC1, GXNPC1, GXCPC1 and GXIPC1, which the indications are liver cirrhosis, stroke, osteoarthritis and diabetes, respectively.



More Information